Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 문영철 | * |
dc.date.accessioned | 2020-06-08T16:30:15Z | - |
dc.date.available | 2020-06-08T16:30:15Z | - |
dc.date.issued | 2020 | * |
dc.identifier.issn | 0939-5555 | * |
dc.identifier.issn | 1432-0584 | * |
dc.identifier.other | OAK-26979 | * |
dc.identifier.uri | https://dspace.ewha.ac.kr/handle/2015.oak/254041 | - |
dc.description.abstract | Epstein-Barr virus (EBV) positivity in diffuse large B cell lymphoma (DLBCL) provokes a critical oncogenic mechanism to activate intracellular signaling by LMP1. LMP1 specifically mimics the role of BTK-dependent B cell receptor. Therefore, a trial considering RCHOP therapy along with ibrutinib (I-RCHOP) in combination was conducted among patients with EBV-positive DLBCL. This study was an open-label, single-arm, prospective multicenter phase II clinical trial. Patients received 560 mg of ibrutinib with RCHOP every 3 weeks until 6 cycles were completed or progression or unacceptable toxicity was observed. The primary endpoint was objective response, while secondary endpoints included toxicity, progression-free survival, and overall survival. A matched case-control analysis was completed to compare the efficacy and toxicity of I-RCHOP and RCHOP, respectively, in EBV-positive DLBCL patients. From September 2016 to August 2019, 24 patients proven to have EBV-positive DLBCL in the tissue were enrolled and received I-RCHOP. Their median age was 58 years (range, 28-84 years). The objective overall response was 66.7%, including 16 patients who achieved complete response after 6 cycles. Patients aged younger than 65 years presented a superior OR (87.5%) as compared with those older than 65 years (25.0%; p = 0.01). In a matched case-control study, I-RCHOP therapy provoked a more favorable complete response rate (87.3%) than did RCHOP (68.8%) in those younger than 65 years. Treatment-related mortality was linked most frequently with I-RCHOP therapy (four patients presented with unusual infection without Gr3/4 neutropenia) in the older age group (age >= 65 years). In conclusion, in this phase II trial for EBV-positive DLBCL, I-RCHOP was effective but did not show a significant improvement in response and survival in comparison with RCHOP. Also, I-RCHOP promoted serious toxicity and treatment-related death in older patients. | * |
dc.language | English | * |
dc.publisher | SPRINGER | * |
dc.subject | Ibrutinib | * |
dc.subject | R-CHOP | * |
dc.subject | Epstein-Barr virus-positive | * |
dc.subject | Diffuse large B cell lymphoma | * |
dc.title | A phase II study of ibrutinib in combination with rituximab-cyclophosphamide-doxorubicin hydrochloride-vincristine sulfate-prednisone therapy in Epstein-Barr virus-positive, diffuse large B cell lymphoma (54179060LYM2003: IVORY study): results of the final analysis | * |
dc.type | Article | * |
dc.relation.issue | 6 | * |
dc.relation.volume | 99 | * |
dc.relation.index | SCIE | * |
dc.relation.index | SCOPUS | * |
dc.relation.startpage | 1283 | * |
dc.relation.lastpage | 1291 | * |
dc.relation.journaltitle | ANNALS OF HEMATOLOGY | * |
dc.identifier.doi | 10.1007/s00277-020-04005-6 | * |
dc.identifier.wosid | WOS:000528434900003 | * |
dc.author.google | Yoon, Sang Eun | * |
dc.author.google | Kim, Seok Jin | * |
dc.author.google | Yoon, K. Hyun | * |
dc.author.google | Koh, Youngil | * |
dc.author.google | Mun, Yeung-Chul | * |
dc.author.google | Do, Young Rok | * |
dc.author.google | Choi, Yoon Seok | * |
dc.author.google | Yang, Deok Hwan | * |
dc.author.google | Kim, Min Kyoung | * |
dc.author.google | Lee, Gyeong-Won | * |
dc.author.google | Suh, Cheolwon | * |
dc.author.google | Ko, Young Hyeh | * |
dc.author.google | Kim, Won Seog | * |
dc.contributor.scopusid | 문영철(7003363716) | * |
dc.date.modifydate | 20240422115947 | * |